University of Calgary
UofC Navigation

Pilot trial on catheter-related thrombosis in cancer patients

Submitted by dawn.smith on Fri, 05/05/2017 - 8:26am
Date: 
Fri, 05/05/2017 - 08:23

Libin Institute member Dr. Deepa Suryanarayan, MD, recently received $59,000 in CanVECTOR funding for a pilot trial on catheter-related thrombosis in cancer patients.

Suryanarayan, who is also a clinical associate professor in the University of Calgary’s Cumming School of Medicine, said the money will be used to test the feasibility of doing a larger study looking at using oral versus intravenous anticoagulants in cancer patients with catheter related thrombosis.

“We are trying to establish whether we can actually do the larger study,” said Suryanarayan, noting taking the time to prove a larger randomized study is feasible helps save the health-care system money and time in the long run.

Suryanarayan, who joined the Libin Institute just a few months ago, earned her medical degree in India before completing a master’s degree in health research methodology from McMaster University in Hamilton, Ont. She completed a hematology fellowship at the University of Calgary.

She returned to Calgary about a year ago and has set up a busy clinical practice.

Over the years, the clinical trialist has developed an interest in researching the safety and efficacy of novel direct oral anticoagulant medications, especially in special populations such as cancer patients.

Suryanarayan explained cancer patients have an increased risk of developing blood clots (thrombosis) in the intravenous lines that deliver medication and may be required for up to three months.

Currently, these patients are given injectable blood thinners to treat and minimize the risk of clots, despite the fact that new, oral blood thinners are available that may make treatment easier for patients.

That’s because, according to Suryanarayan, the treatments remain largely untested in cancer patients.

If Suraynarayan’s larger study takes place, she will be testing apixaban versus low molecular weight heparin (LMWH) in cancer patients. She is hoping her research will contribute to a new standard of care that eases the burden for patients.

Suryanarayan is in the process of setting up a cancer thrombosis clinic, and she is hoping to start recruiting patients for her feasibility study by late fall. The trial will run for between eight to 10 months.

It is Suryanarayan’s first time as the principal investigator in a multi-site trial of this kind.

She will be working alongside co-principal investigators in Edmonton and senior investigator Dr. Marc Carrier, MD, the vice chair of research for the Department of Medicine at the University of Ottawa.  

She is excited by the project and hopes that this pilot will help strengthen thrombosis research program at the University of Calgary.  

The Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network is a pan-Canadian, patient-oriented, Community Development Program centred on venous thromboembolism related research, training and knowledge translation.

 

 

 

 

Connect with Us

Our Partners

Alvin and Mona Libin Foundation

Our Publications